This research aims to develop and assess new 3-aza-bicyclo[3.3.0]octane compounds that inhibit ERK5 for cancer therapy.
Synthesis of novel 3-aza-bicyclo[3.3.0]octane compounds aimed at ERK5 inhibition.
Assessment of pharmaceutical compositions containing these compounds.
Evaluation of their efficacy in treating cancer.
Demonstrated effective inhibition of ERK5 activity by the new compounds.
Showed promise in preclinical models for cancer treatment.
Abstract
Provided herein are novel 3-aza-bicyclo3.3.0octanecompounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.